Dec 30, 2025 • MarketBeat
BEARISH
Insider Selling: Vaxcyte (NASDAQ:PCVX) SVP Sells 11,623 Shares of Stock
Vaxcyte (NASDAQ:PCVX) SVP Elvia Cowan sold 11,623 shares of the company's stock on December 23rd at an average price of $47.92, totaling approximately $556,974. This transaction reduced her stake by 44.44% to 14,534 shares. The company's stock traded down 0.9% to $46.57, and Vaxcyte also reported a quarterly loss, missing analyst estimates.
Dec 29, 2025 • MSN
SOMEWHAT-BEARISH
Vaxcyte president and CFO sells shares worth $692,100
The President and CFO of Vaxcyte, Inc. (Symbol: PCVX), Grant Pickering, sold 13,000 shares of company stock, valued at approximately $692,100, on December 26, 2025. Following this transaction, Pickering still holds 312,238 shares of Vaxcyte stock. The sale occurred on the open market.
Dec 27, 2025 • MarketBeat
SOMEWHAT-BEARISH
Vaxcyte, Inc. $PCVX Shares Sold by Harbor Capital Advisors Inc.
Harbor Capital Advisors Inc. significantly reduced its stake in Vaxcyte, Inc. ($PCVX) by 69.7% in Q3 2025, selling 71,340 shares. Despite this, institutional investors still hold a dominant 96.78% of the biotech company's stock, with a consensus analyst rating of "Moderate Buy" and a price target of $97.83, significantly above its current trading price of $46.97. Vaxcyte recently missed quarterly EPS expectations.
Dec 22, 2025 • MarketBeat
SOMEWHAT-BULLISH
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Rating of "Moderate Buy" from Analysts
Vaxcyte, Inc. (NASDAQ:PCVX) has received a consensus "Moderate Buy" rating from ten brokerages, with an average 12-month target price of $97.83. Despite missing quarterly EPS estimates, the stock opened up 6.2% and institutional investors own a significant portion of the company. Vaxcyte is a clinical-stage biotechnology firm developing preventive vaccines, with its lead candidate VAX-24, a 24-valent pneumococcal conjugate vaccine.
Dec 22, 2025 • Barron's
SOMEWHAT-BULLISH
This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.
Vaxcyte, a biotechnology company, has an experimental pneumococcal disease vaccine that an analyst from Mizuho Securities believes could be a game-changer in the $8 billion pneumococcal vaccine market. Despite a rough year for the stock, the analyst projects a potential 250% increase, with significant changes expected as early as 2026. This optimism highlights the potential of the vaccine to justify investor hopes in the coming years.
Dec 22, 2025 • Finviz
NEUTRAL
What Makes Vaxcyte (PCVX) So Attractive
Vaxcyte Inc. (PCVX) is highlighted as a promising mid-cap healthcare stock due to positive Phase 2 trial results for its VAX-31 vaccine and strong analyst optimism. BTIG analyst Thomas Shrader reiterated a Buy rating with an $85 price target, and consensus ratings show a median 1-year price target of $100.80, indicating significant upside potential. The company's innovative approach to developing next-generation vaccines for bacterial diseases further adds to its attractiveness.